Advertisement
Advertisement
U.S. markets close in 5 hours 7 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Novozymes A/S (NZM2.BE)

Berlin - Berlin Delayed Price. Currency in EUR
47.24+0.39 (+0.83%)
As of 03:41PM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close46.85
Open47.15
Bid47.41 x 50000
Ask47.61 x 50000
Day's Range46.50 - 47.27
52 Week Range46.06 - 67.02
Volume9
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for NZM2.BE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Novozymes delivers historically strong full-year results

      Novozymes is delivering strong growth and earnings in a volatile market environment with 9% organic sales growth in 2022. This marks the highest organic sales growth in more than a decade, and Novozymes is confident about the 2023 outlook of 4-7%. COPENHAGEN, Denmark – January 26, 2026. In the 2022 financial year, Novozymes delivers 9% organic sales growth – 11% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 26.4%, and ROIC including goodwill before

    • MarketWatch

      Novozymes and Chr. Hansen agree deal to merge

      The Danish companies will create a biological solutions provider with combined annual revenue of around 3.5 billion euros ($3.69 billion).

    Advertisement
    Advertisement